166 related articles for article (PubMed ID: 24590774)
21. Sentinel lymph node biopsy in the management of ductal carcinoma in situ.
Zujewski J; Eng-Wong J
Clin Breast Cancer; 2005 Aug; 6(3):216-22. PubMed ID: 16137431
[TBL] [Abstract][Full Text] [Related]
22. The incidence and significance of micrometastases in lymph nodes of patients with ductal carcinoma in situ and T1a carcinoma of the breast.
Broekhuizen LN; Wijsman JH; Peterse JL; Rutgers EJ
Eur J Surg Oncol; 2006 Jun; 32(5):502-6. PubMed ID: 16569492
[TBL] [Abstract][Full Text] [Related]
23. [Importance of sentinel lymph node biopsy in surgical therapy of in situ breast cancer].
Takács T; Szentpáli K; Paszt A; Ormándi K; Lázár M; Pálka I; Kahán Z; Lázár G
Magy Onkol; 2006; 50(3):247-51. PubMed ID: 17099786
[TBL] [Abstract][Full Text] [Related]
24. Sentinel lymph node biopsy in contralateral prophylactic mastectomy: are we overtreating? Experience at a tertiary care hospital.
Kuwajerwala NK; Dekhne NS; Pentiak PA; Fend D; Callahan RE; Amine M; Lucia V; Swartz J
Clin Breast Cancer; 2013 Aug; 13(4):287-91. PubMed ID: 23706482
[TBL] [Abstract][Full Text] [Related]
25. Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer.
Hartkopf AD; Stefanescu D; Wallwiener M; Hahn M; Becker S; Solomayer EF; Fehm TN; Brucker SY; Taran FA
Breast Cancer Res Treat; 2014 Sep; 147(2):345-51. PubMed ID: 25151295
[TBL] [Abstract][Full Text] [Related]
26. Ductal carcinoma in situ: value of sentinel lymph node biopsy.
Sakr R; Barranger E; Antoine M; Prugnolle H; Daraï E; Uzan S
J Surg Oncol; 2006 Oct; 94(5):426-30. PubMed ID: 16967457
[TBL] [Abstract][Full Text] [Related]
27. An argument against routine sentinel node mapping for DCIS.
Farkas EA; Stolier AJ; Teng SC; Bolton JS; Fuhrman GM
Am Surg; 2004 Jan; 70(1):13-7; discussion 17-8. PubMed ID: 14964539
[TBL] [Abstract][Full Text] [Related]
28. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up.
Lara JF; Young SM; Velilla RE; Santoro EJ; Templeton SF
Cancer; 2003 Nov; 98(10):2105-13. PubMed ID: 14601079
[TBL] [Abstract][Full Text] [Related]
29. Predictors of treatment with mastectomy, use of sentinel lymph node biopsy and upstaging to invasive cancer in patients diagnosed with breast ductal carcinoma in situ (DCIS) on core biopsy.
Chin-Lenn L; Mack LA; Temple W; Cherniak W; Quinn RR; Ravani P; Lewin AM; Quan ML
Ann Surg Oncol; 2014 Jan; 21(1):66-73. PubMed ID: 24046105
[TBL] [Abstract][Full Text] [Related]
30. Ductal carcinoma in situ with microinvasion: prognostic implications, long-term outcomes, and role of axillary evaluation.
Parikh RR; Haffty BG; Lannin D; Moran MS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):7-13. PubMed ID: 20950955
[TBL] [Abstract][Full Text] [Related]
31. Predictors of local recurrence following excision alone for ductal carcinoma in situ.
Hetelekidis S; Collins L; Silver B; Manola J; Gelman R; Cooper A; Lester S; Lyons JA; Harris JR; Schnitt SJ
Cancer; 1999 Jan; 85(2):427-31. PubMed ID: 10023711
[TBL] [Abstract][Full Text] [Related]
32. The frequency of presentation and clinico-pathological characteristics of symptomatic versus screen detected ductal carcinoma in situ of the breast.
Barnes NL; Dimopoulos N; Williams KE; Howe M; Bundred NJ
Eur J Surg Oncol; 2014 Mar; 40(3):249-54. PubMed ID: 24433818
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study.
Altintas S; Lambein K; Huizing MT; Braems G; Asjoe FT; Hellemans H; Van Marck E; Weyler J; Praet M; Van den Broecke R; Vermorken JB; Tjalma WA
Breast J; 2009; 15(2):120-32. PubMed ID: 19292797
[TBL] [Abstract][Full Text] [Related]
34. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer.
Katz A; Gage I; Evans S; Shaffer M; Fleury T; Smith FP; Flax R; Drogula C; Petrucci P; Magnant C
Am J Surg; 2006 Jun; 191(6):761-6. PubMed ID: 16720145
[TBL] [Abstract][Full Text] [Related]
35. [The role of sentinel lymph node biopsy in breast cancer non-invading-duct].
Török K; Péley G; Mátrai Z; Bidlek M; Szabó E; Sinkovics I; Polgár C; Farkas E; Orosz Z; Köves I
Magy Seb; 2006 Jun; 59(3):173-8. PubMed ID: 16937792
[TBL] [Abstract][Full Text] [Related]
36. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone.
Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R
Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334
[TBL] [Abstract][Full Text] [Related]
37. [Ductal carcinoma in situ of the breast with microinvasion. Role of sentinel lymph node biopsy].
Le Bouëdec G; de Lapasse C; Mishellany F; Chêne G; Michy T; Gimbergues P; Dauplat J
Gynecol Obstet Fertil; 2007 Apr; 35(4):317-22. PubMed ID: 17344087
[TBL] [Abstract][Full Text] [Related]
38. An update of sentinel lymph node mapping in patients with ductal carcinoma in situ.
Wilkie C; White L; Dupont E; Cantor A; Cox CE
Am J Surg; 2005 Oct; 190(4):563-6. PubMed ID: 16164920
[TBL] [Abstract][Full Text] [Related]
39. Detection of disseminated tumor cells in patients with gynecological cancers.
Fehm T; Becker S; Bachmann C; Beck V; Gebauer G; Banys M; Wallwiener D; Solomayer EF
Gynecol Oncol; 2006 Dec; 103(3):942-7. PubMed ID: 16889820
[TBL] [Abstract][Full Text] [Related]
40. [Cytoplasmic expression of aquaporin-1 in breast cancer cells and its relationship with clinicopathological characteristics and prognosis].
Zhang B; Liu FF; Ma YJ; Gu F
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):904-9. PubMed ID: 24506959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
